- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
E-Z-EM names new U.K. general manager
Gastrointestinal contrast agent developer E-Z-EM of Westbury, NY, this month appointed David Wills as general manager for its U.K. subsidiary, E-Z-EM Ltd. of London. Wills plans to focus on bolstering the company’s share in the U.K. barium sulfate
Gastrointestinal contrast agent developer E-Z-EM of Westbury, NY, this month appointed David Wills as general manager for its U.K. subsidiary, E-Z-EM Ltd. of London. Wills plans to focus on bolstering the companys share in the U.K. barium sulfate contrast market. He comes to E-Z-EM from Medtronic U.K. Ltd., where he served as business development manager for that firms peripheral vascular division. Wills brings 16 years of medical device sales experience to his new post.
Emerging Perspectives on PSMA PET Radiotracers: An Interview with Kenneth J. Pienta, MD
April 24th 2024In a recent interview, Kenneth J. Pienta, M.D., discussed the impact of piflufolastat F18, current directions in research with other PSMA-targeted radiotracers and future possibilities for the role of PSMA PET in the imaging paradigm for prostate cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.
